GETI.B

210

+0.43%↑

CAMX

609

-0.41%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

GETI.B

210

+0.43%↑

CAMX

609

-0.41%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

GETI.B

210

+0.43%↑

CAMX

609

-0.41%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

GETI.B

210

+0.43%↑

CAMX

609

-0.41%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

GETI.B

210

+0.43%↑

CAMX

609

-0.41%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

Strona główna・Stock List・BioArctic AB

B
BioArctic AB

Closed

320.2 -0.12

Buy Sell

Overview

Share price change

24h

Current

Min

319.2

Max

320.4

Key metrics
By Trading Economics
Income	-208M -29M
Sales	-259M 133M
P/E Sector Avg	28.167 77.671
EPS	-0.98
Profit margin	-21.576
Employees	122
EBITDA	-206M -18M

Market Stats
By TradingEconomics
Market Cap	2.2B 28B
Previous open	320.32
Previous close	320.2

BioArctic AB Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 gru 2025, 00:04 UTC

Acquisitions, Mergers, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12 gru 2025, 16:42 UTC

Acquisitions, Mergers, Takeovers

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13 gru 2025, 16:48 UTC

Acquisitions, Mergers, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 gru 2025, 08:00 UTC

Acquisitions, Mergers, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 gru 2025, 07:00 UTC

Acquisitions, Mergers, Takeovers

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 gru 2025, 00:24 UTC

Acquisitions, Mergers, Takeovers

Want a Piece Of SpaceX? -- Barrons.com

12 gru 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 gru 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 gru 2025, 22:32 UTC

Earnings

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 gru 2025, 20:45 UTC

Earnings

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 gru 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 gru 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 gru 2025, 19:23 UTC

Earnings

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 gru 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 gru 2025, 18:33 UTC

Acquisitions, Mergers, Takeovers

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 gru 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 gru 2025, 17:49 UTC

Earnings

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 gru 2025, 17:34 UTC

Acquisitions, Mergers, Takeovers

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 gru 2025, 17:33 UTC

Acquisitions, Mergers, Takeovers

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 gru 2025, 17:33 UTC

Acquisitions, Mergers, Takeovers

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 gru 2025, 17:32 UTC

Acquisitions, Mergers, Takeovers

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 gru 2025, 17:31 UTC

Acquisitions, Mergers, Takeovers

Orange to Buy the Stake for EU4.25B in Cash

12 gru 2025, 17:24 UTC

Market Talk

Argentina Predicts Record Wheat Crop -- Market Talk

12 gru 2025, 17:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

12 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 gru 2025, 17:18 UTC

Market Talk

Earnings

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 gru 2025, 17:09 UTC

Market Talk

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 gru 2025, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 gru 2025, 16:47 UTC

Market Talk

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

Peer Comparison

Price change

BioArctic AB Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.